IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion-Reference-Cited by-同舟云学术

IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion

Published:2019-05-29 Issue:16 Volume:25 Page:4945-4954
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Conlon Kevin C.,Potter E. Lake,Pittaluga Stefania,Lee Chyi-Chia Richard,Miljkovic Milos D.,Fleisher Thomas A.,Dubois Sigrid,Bryant Bonita R.,Petrus Michael,Perera Liyanage P.,Hsu Jennifer,Figg William D.^ORCID,Peer Cody J.,Shih Joanna H.,Yovandich Jason L.,Creekmore Stephen P.,Roederer Mario,Waldmann Thomas A.

Funder

Intramural Research Program of the Center for Cancer ResearchNCINational Institute of Allergy and Infectious DiseasesNIHNational Institute of Allergy and Infectious DiseasesNIH

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. References;The Evolution of Immunotherapy Against Tumors;2025

2. Dual and multi-immune activation strategies for emerging cancer immunotherapy;Materials Today;2024-09

3. Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia;International Journal of Molecular Sciences;2024-08-30

4. Stimulating the Antitumor Immune Response Using Immunocytokines: A Preclinical and Clinical Overview;Pharmaceutics;2024-07-24

5. Translational PK/PD and the first-in-human dose selection of a PD1/IL15: an engineered recombinant targeted cytokine for cancer immunotherapy;Frontiers in Pharmacology;2024-06-03